CNS Pharmaceuticals reports Q3 results
- CNS Pharmaceuticals press release (NASDAQ:CNSP): Q3 Net loss of $3.4M
As of September 30, 2022, the Company had cash of approximately $7.0 million and working capital of approximately $7.5 million. The Company's current expectation is that the cash on hand and the proceeds from the offering during January is sufficient to fund our operations into the first quarter of 2023.
- Shares -2.42% PM.